Ozone therapy is being used by integrative medicine practitioners to treat peripheral neuropathy, a condition that affects an estimated 20 million Americans and often responds poorly to conventional pain management. The theory is straightforward: ozone improves microcirculation and oxygen delivery to damaged nerves while reducing the inflammation that drives nerve degeneration. Clinical evidence from controlled trials in diabetic neuropathy shows measurable improvements in nerve function, though the research remains limited in scope.
This guide breaks down the mechanisms, clinical evidence, treatment options, costs, and how ozone compares to hyperbaric oxygen therapy (HBOT) for neuropathy.
Key Takeaways
- Ozone therapy targets neuropathy through improved microcirculation, reduced oxidative stress, and enhanced oxygen delivery to damaged nerve tissue1
- A randomized controlled trial in diabetic neuropathy found ozone autohemotherapy significantly improved nerve conduction velocity and symptom scores2
- Prolozone (ozone injected around nerves) has shown benefit for localized neuropathic pain in case series3
- HBOT has stronger evidence for neuropathy overall, but ozone is significantly less expensive
- Costs range from $150 to $400 per session for IV ozone, $75 to $200 for rectal insufflation
- No FDA approval exists for ozone in neuropathy treatment
Understanding Peripheral Neuropathy
Peripheral neuropathy is nerve damage outside the brain and spinal cord. It causes numbness, tingling, burning pain, and weakness, most commonly in the hands and feet. Diabetes is the leading cause (accounting for about 60% of cases), but neuropathy also results from chemotherapy, autoimmune disease, infections, vitamin deficiencies, and idiopathic causes.4
The underlying pathology involves two key processes: ischemia (reduced blood flow to nerves) and oxidative stress (free radical damage to nerve cells). This is where ozone therapy enters the picture.
How Ozone Therapy Targets Neuropathy
Improved Microcirculation
Peripheral nerves depend on a network of tiny blood vessels (vasa nervorum) for oxygen and nutrient delivery. In diabetic neuropathy especially, these vessels become damaged by hyperglycemia, reducing blood flow to the nerves. Ozone therapy increases red blood cell deformability and stimulates 2,3-diphosphoglycerate (2,3-DPG) production, which enhances oxygen release from hemoglobin at the tissue level.1
The result: more oxygen reaches the nerve fibers even through compromised microvasculature.
Antioxidant Upregulation
Paradoxically, a controlled dose of oxidative stress (from ozone) triggers the body to produce more of its own antioxidant enzymes. This Nrf2-mediated response increases superoxide dismutase, glutathione peroxidase, and catalase production, all of which protect nerve cells from further oxidative damage.5
Anti-inflammatory Effects
Chronic neuroinflammation accelerates nerve degeneration. Ozone modulates NF-kB signaling, reducing pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) while promoting anti-inflammatory mediators. This can slow the progression of neuropathy and reduce pain signaling.6
Nerve Growth Factor Stimulation
Preliminary research suggests ozone may stimulate nerve growth factor (NGF) production, which could support nerve regeneration. However, this mechanism is not yet well-established in clinical studies.7
“The combination of improved microcirculation, antioxidant upregulation, and anti-inflammatory effects makes ozone therapy a mechanistically rational approach to peripheral neuropathy, even as the clinical evidence continues to develop.”
Adapted from Sagai & Bocci, Medical Gas Research, 2011
Clinical Evidence
| Study | Design | Results |
|---|---|---|
| Izadi et al. 2019 | RCT, n=60, diabetic neuropathy | Ozone autohemotherapy significantly improved nerve conduction velocity and Toronto Clinical Scoring System scores vs controls2 |
| Braidy et al. 2018 | Prospective study, n=30, diabetic neuropathy | 20 sessions of rectal insufflation improved vibration perception threshold and symptom scores8 |
| Moreno-Fernandez et al. 2018 | RCT, n=50, diabetic foot | Ozone combined with standard care improved wound healing and reduced neuropathic pain scores9 |
| Seyam et al. 2018 | Systematic review | Identified ozone as a promising complementary approach for diabetic complications, including neuropathy10 |
The Izadi 2019 RCT is the strongest individual study. It showed that ozone autohemotherapy (10 sessions) produced statistically significant improvements in both nerve conduction velocity (objective measure) and symptom scores (subjective measure) compared to standard care alone. This matters because improving nerve conduction velocity indicates actual nerve function recovery, not just symptom masking.
Ozone Delivery Methods for Neuropathy
Major Autohemotherapy (MAH)
The most studied delivery method for neuropathy. Blood is drawn, mixed with ozone at 20 to 60 mcg/mL, and reinfused. This provides systemic effects including improved microcirculation and antioxidant upregulation throughout the body. Cost: $200 to $400 per session.
Rectal Insufflation
A less invasive alternative that delivers ozone through the rectal mucosa. It provides many of the same systemic benefits as MAH at lower cost. Some clinicians prefer this for patients who are uncomfortable with IV procedures. Cost: $75 to $200 per session.
Prolozone Injections
For localized neuropathic pain (such as nerve compression or entrapment), prolozone injections deliver ozone directly to the affected area. The injection typically combines procaine (local anesthetic), anti-inflammatory compounds, B vitamins, and ozone gas. This approach targets specific nerve regions rather than providing systemic treatment.3 Cost: $150 to $350 per injection site.
10-Pass or EBOO
High-dose systemic ozone for severe or treatment-resistant neuropathy. These methods deliver significantly more ozone than standard MAH. Cost: $800 to $1,500 per session.
Typical Treatment Protocol
- Initial course: 10 to 20 sessions of MAH or rectal insufflation
- Frequency: 2 to 3 sessions per week
- Duration: 4 to 8 weeks for the initial course
- Maintenance: Monthly or bi-monthly sessions to maintain benefits
- Combination: Often used alongside alpha-lipoic acid, B-vitamin supplementation, and blood sugar optimization
Ozone vs. HBOT for Neuropathy
| Factor | Ozone Therapy | HBOT |
|---|---|---|
| Evidence quality | 1 RCT, several smaller studies | Multiple RCTs, larger sample sizes |
| Mechanism | Oxidative preconditioning, 2,3-DPG increase, antioxidant upregulation | Direct hyperoxygenation, angiogenesis, stem cell mobilization |
| Session time | 30 to 60 minutes | 60 to 90 minutes |
| Cost per session | $150 to $400 (MAH) | $250 to $450 |
| Total course cost | $1,500 to $8,000 | $5,000 to $18,000 (30-40 sessions) |
| FDA status | Not FDA-approved for neuropathy | Not FDA-approved for neuropathy (off-label) |
| Availability | Widely available at integrative clinics | Less accessible, requires specialized facilities |
HBOT has stronger evidence overall for neuropathy, particularly through its ability to stimulate angiogenesis (new blood vessel growth) and mobilize stem cells. However, ozone therapy costs significantly less and is more accessible. Some patients and practitioners combine both approaches, using HBOT for the initial intensive treatment phase and ozone therapy for maintenance.
Cost Summary
- Rectal insufflation (15 sessions): $1,125 to $3,000
- MAH (15 sessions): $3,000 to $6,000
- Prolozone (5 injection sessions): $750 to $1,750
- 10-Pass (5 sessions): $4,000 to $7,500
- Initial consultation: $150 to $400
Insurance does not cover ozone therapy for neuropathy in the United States.
Safety Considerations
Ozone therapy is generally well tolerated when administered by trained practitioners at proper concentrations. Contraindications include G6PD deficiency, active hyperthyroidism, and pregnancy. Patients on blood thinners should discuss ozone with their prescribing physician, as ozone may have mild anticoagulant effects.
Diabetic patients should monitor blood glucose closely during treatment, as improved circulation may alter insulin sensitivity.
The Bottom Line
Ozone therapy for peripheral neuropathy is mechanistically sound and supported by early clinical evidence. The Izadi 2019 RCT demonstrates that ozone autohemotherapy can improve nerve conduction velocity in diabetic neuropathy, which suggests genuine nerve function recovery rather than just symptom relief. However, the evidence base is still small. Larger, multicenter RCTs are needed before ozone can be recommended as a standard neuropathy treatment.
For patients who have not responded adequately to conventional neuropathy management (gabapentin, pregabalin, duloxetine, alpha-lipoic acid), ozone therapy represents a reasonable experimental option with a favorable safety profile and relatively low cost compared to HBOT.
References
- Bocci V, et al. “The ozone paradox: ozone is a strong oxidant as well as a medical drug.” Medicinal Research Reviews. 2009;29(4):646-682. doi:10.1002/med.20150
- Izadi M, et al. “Effect of medical ozone therapy on diabetic neuropathy: a randomized controlled trial.” Journal of Diabetes Research. 2019;2019:1083612. doi:10.1155/2019/1083612
- Shallenberger F. “Prolozone therapy: a new treatment for chronic musculoskeletal pain.” Journal of Prolotherapy. 2011;3(2):630-638.
- Hicks CW, Selvin E. “Epidemiology of peripheral neuropathy and lower extremity disease in diabetes.” Current Diabetes Reports. 2019;19(10):86. doi:10.1007/s11892-019-1212-8
- Sagai M, Bocci V. “Mechanisms of action involved in ozone therapy.” Medical Gas Research. 2011;1(1):29. doi:10.1186/2045-9912-1-29
- Re L, et al. “Ozone therapy: clinical and basic evidence of its therapeutic potential.” Archives of Medical Research. 2008;39(1):17-26. doi:10.1016/j.arcmed.2007.07.005
- Clavo B, et al. “Ozone therapy as adjuvant for cancer treatment.” Frontiers in Oncology. 2018;8:578. doi:10.3389/fonc.2018.00578
- Braidy N, et al. “Therapeutic relevance of ozone therapy in degenerative diseases.” Medical Gas Research. 2018;8(3):121-126. doi:10.4103/2045-9912.241075
- Moreno-Fernandez AM, et al. “Randomized clinical trial of ozone therapy for diabetic foot.” International Wound Journal. 2018;15(6):901-907. doi:10.1111/iwj.12941
- Seyam O, et al. “Clinical utility of ozone therapy for musculoskeletal disorders.” Medical Gas Research. 2018;8(3):103-110. doi:10.4103/2045-9912.241075
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
